Rani Therapeutics Holdings, Inc. (RANI) Stock Price & Analysis
Rani Therapeutics Holdings, Inc. (RANI) — MoonshotScore 21/100 (Weak band), calculated Oct 5, 2026. Price $0.8108 (+1.92%), as of the Oct 2, 2026 trading session; market cap $53.0M.
Educational signal · not a buy or sell recommendation · How to read this
Rani Therapeutics Holdings, Inc. · RANI · NASDAQ
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on developing orally administered biologics using its RaniPill capsule technology. The company aims to replace subcutaneous or IV injections with oral dosing for various therapeutic areas.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Rani Therapeutics Holdings (RANI)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality and an expensive valuation. Business Quality: Poor; Financial Safety: Sound; Valuation: Rich; Growth Durability: Growing; Momentum: Quiet.
- quarterly revenue $2M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 3 of 8
- Altman Z -1.70 · Piotroski F 5
Holding back: weak fundamentals, a rich price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak |
The score was 21 in the stored Oct 4, 2026 snapshot and remains 21 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability -1 and Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.8108 |
| Change on the day | +1.92% |
| 52-week range | $0.445 – $3.87 |
| Market capitalisation | $53.0M |
| Shares traded on the day | 418.5K |
Price & events
Council Score · weighted blend of 2 available disciplines
Council score for Rani Therapeutics Holdings (RANI): Split View
39/100 · DSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the RANI film — every key number, told as a short cinematic story
~2 min · open the film
What is Rani Therapeutics Holdings (RANI), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Rani Therapeutics Holdings, Inc. (RANI) is listed on NASDAQ. It employs 70 people and is led by Talat Imran. In Q2 FY2026 it reported revenue of $2M and net income of -$7M. The market values it at $53.0M.
What do the latest results show for Rani Therapeutics Holdings (RANI)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $2M. Against analyst estimates the company has EPS beat 3 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $2M | -$7M | -$0.04 (diluted) |
| Q1 FY2026 | $2M | -$7M | -$0.04 (diluted) |
| Q4 FY2025 | $1M | -$10M | -$0.07 (diluted) |
| Q3 FY2025 | $0 | -$5M | -$0.15 (diluted) |
What are the financial strengths and risks for Rani Therapeutics Holdings (RANI)?
Short answer
What is holding it back is weak fundamentals, a rich price. The distress and quality screens read Altman Z -1.70 · Piotroski F 5. Trailing ratios: ROA -49.5% · current ratio 5.31 · earnings yield -20.4% · free-cash-flow yield -39.4%.
Data-derived red flags
- Listing risk — at $0.8108 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -1.70 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
How does Rani Therapeutics Holdings compare with its peers?
Short answer
Rani Therapeutics Holdings's score ranks 4th of 4 in the bounded comparison shown, against 3 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $504.73 Oct 2, 2026 | $128B | 97 5-pillar Oct 5, 2026 | |
| $1142.85 Oct 2, 2026 | $1.08T | 97 5-pillar Oct 5, 2026 | |
| $37.32 Oct 2, 2026 | $166B | 91 5-pillar Oct 5, 2026 | |
| Rani Therapeutics Holdings (RANI) — this page | $0.8108 | $53.0M | 21 |
| $9.75 Date unavailable | $88.2M | — Model unavailable | |
| $17.08 Date unavailable | $90.6M | — Model unavailable | |
| $9.96 Date unavailable | $119M | — Model unavailable | |
| $4.49 Date unavailable | $184M | — Model unavailable | |
| $5.71 Date unavailable | $206M | — Model unavailable | |
| $2.71 Date unavailable | $218M | — Model unavailable | |
| $2.79 Date unavailable | $222M | — Model unavailable | |
| $8.23 Date unavailable | $245M | — Model unavailable | |
| $7.19 Date unavailable | $564M | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
What has been published about Rani Therapeutics Holdings (RANI)?
Investor Questions: RANI Stock
These answers are editorial: 1 of these 9 answers is drawn from the RANI research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for RANI?
RANI carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is RANI a good stock to buy?
Stock Expert AI does not rate RANI buy, sell or hold. Rani Therapeutics Holdings, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RANI stock price today?
The last price recorded on this page for Rani Therapeutics Holdings, Inc. (RANI) is $0.8108, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about RANI stock?
Analyst coverage of Rani Therapeutics Holdings, Inc. is still emerging, reflecting its clinical-stage status. Key valuation metrics focus on the potential of the RaniPill technology and the success of its clinical trials.
What are the key factors to evaluate for RANI?
Rani Therapeutics Holdings, Inc. (RANI) holds a MoonshotScore in the low range. This would provide the company with additional funding and expertise, while also expanding its market reach. Not financial advice.
How frequently does RANI data refresh on this page?
RANI's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RANI's recent stock price performance?
Rani Therapeutics Holdings, Inc. (RANI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative RaniPill capsule technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RANI overvalued or undervalued right now?
Rani Therapeutics Holdings, Inc. (RANI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of RANI?
Fractional-share availability for Rani Therapeutics Holdings, Inc. (RANI) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (16 figures)
The 16 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.8108 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T06:34:27.234Z. | |
px.change | Change on the day | +1.92% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $53.0M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T06:34:26.198Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.0153 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $2M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.volume | Shares traded on the day | 418.5K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q2 FY2026 | -$7M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-16 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -1.70 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
px.range52 | 52-week range | $0.445 – $3.87 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.employees | Employees | 70 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.ceo | Chief executive | Talat Imran | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROA -49.5% · current ratio 5.31 · earnings yield -20.4% · free-cash-flow yield -39.4% | — | UNRECORDED | Stored key metrics — Date unknown |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 21 of 100 · Weak · pillars 19 / 64 / 23 / 67 / 59 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 21 (stored snapshot Oct 4, 2026) → 21 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.